DE2530090A1 - Mittel zur immunologischen und immunotherapeutischen kontrolle von schistosomiasis und tumorwachstum oder fasciolosis - Google Patents
Mittel zur immunologischen und immunotherapeutischen kontrolle von schistosomiasis und tumorwachstum oder fasciolosisInfo
- Publication number
- DE2530090A1 DE2530090A1 DE19752530090 DE2530090A DE2530090A1 DE 2530090 A1 DE2530090 A1 DE 2530090A1 DE 19752530090 DE19752530090 DE 19752530090 DE 2530090 A DE2530090 A DE 2530090A DE 2530090 A1 DE2530090 A1 DE 2530090A1
- Authority
- DE
- Germany
- Prior art keywords
- immunological
- infection
- fasciolosis
- control
- immunotherapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006275 fascioliasis Diseases 0.000 title claims description 12
- 230000001900 immune effect Effects 0.000 title claims description 8
- 230000001024 immunotherapeutic effect Effects 0.000 title claims description 7
- 230000004614 tumor growth Effects 0.000 title claims description 5
- 201000004409 schistosomiasis Diseases 0.000 title description 5
- 241000237858 Gastropoda Species 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 11
- 241000754688 Cercaria Species 0.000 claims description 8
- 241000237354 Lymnaea Species 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 4
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 2
- YRHRIQCWCFGUEQ-UHFFFAOYSA-N thioxanthen-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3SC2=C1 YRHRIQCWCFGUEQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 description 26
- 239000000243 solution Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 10
- 235000013601 eggs Nutrition 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000029142 excretion Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 244000045947 parasite Species 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 241000242711 Fasciola hepatica Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 241000242678 Schistosoma Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- AINFFKFGHUKSDZ-UHFFFAOYSA-N 5-[2-(diethylamino)ethylamino]-1,2,3,4-tetrahydrobenzo[c]thioxanthen-7-one Chemical compound C1CCCC2=C1C(SC=1C(=CC=CC=1)C1=O)=C1C=C2NCCN(CC)CC AINFFKFGHUKSDZ-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7409359A SE7409359L (sv) | 1974-07-17 | 1974-07-17 | Immunologisk och immunoterapeutisk kontroll av schistosomiasisinfektion och tumortillvext med kemiskt forbehandlade cerkarier. |
| SE7409589A SE7409589L (sv) | 1974-07-23 | 1974-07-23 | Immunologisk och immunoterapeutisk kontroll av fascioliasisinfektion genom: a)extrakt fran kemiskt forbehandlade sniglar av lymnae-typ eller b)kemiskt forbehandlade metacerkarier. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2530090A1 true DE2530090A1 (de) | 1976-01-29 |
Family
ID=26656508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752530090 Pending DE2530090A1 (de) | 1974-07-17 | 1975-07-05 | Mittel zur immunologischen und immunotherapeutischen kontrolle von schistosomiasis und tumorwachstum oder fasciolosis |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5135416A (enExample) |
| DE (1) | DE2530090A1 (enExample) |
| DK (1) | DK323975A (enExample) |
| FI (1) | FI752064A7 (enExample) |
| FR (1) | FR2278346A1 (enExample) |
| LU (1) | LU73006A1 (enExample) |
| NL (1) | NL7508588A (enExample) |
| NO (1) | NO752525L (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61141196A (ja) * | 1984-12-13 | 1986-06-28 | 神東塗料株式会社 | 微細な導電性パターンを有する基体の選択接着方法 |
-
1975
- 1975-07-05 DE DE19752530090 patent/DE2530090A1/de active Pending
- 1975-07-15 NO NO752525A patent/NO752525L/no unknown
- 1975-07-16 FR FR7522187A patent/FR2278346A1/fr not_active Withdrawn
- 1975-07-16 FI FI752064A patent/FI752064A7/fi not_active Application Discontinuation
- 1975-07-16 DK DK323975A patent/DK323975A/da unknown
- 1975-07-17 LU LU73006A patent/LU73006A1/xx unknown
- 1975-07-17 NL NL7508588A patent/NL7508588A/xx unknown
- 1975-07-17 JP JP50086733A patent/JPS5135416A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI752064A7 (enExample) | 1976-01-18 |
| FR2278346A1 (fr) | 1976-02-13 |
| JPS5135416A (en) | 1976-03-25 |
| LU73006A1 (enExample) | 1976-07-01 |
| NO752525L (enExample) | 1976-01-20 |
| DK323975A (da) | 1976-01-18 |
| NL7508588A (nl) | 1976-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3036458C2 (enExample) | ||
| DE2655844A1 (de) | Verfahren zur herstellung antitumorerzeugender substanzen | |
| DE2409862C3 (de) | Verwendung einer oral applizierbaren Immunoglobulinkombination | |
| EP2497480A1 (de) | Extrakte aus phototrophen Mikroorganismen als Adjuvans | |
| DE3834729A1 (de) | Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen | |
| DE3750225T2 (de) | Herstellung und verwendung von anti-helminthischen wirkstoffen und schutzantigenen. | |
| DE69231093T2 (de) | Verwendung einer zellulären Zusammensetzung zur Behandlung von menschlichen oder tierischen Organismen | |
| DE2444299A1 (de) | Impfstoffe gegen katzen-leukaemie | |
| CH452111A (de) | Verfahren zur Herstellung eines Impfstoffes | |
| DE3783409T2 (de) | Verfahren zur besserung der qualitaet von tieren. | |
| DE3010041C2 (de) | Arzneimittel zur Behandlung von parasitärem Wurmbefall | |
| DE2530090A1 (de) | Mittel zur immunologischen und immunotherapeutischen kontrolle von schistosomiasis und tumorwachstum oder fasciolosis | |
| DE1017744B (de) | Verfahren zur Gewinnung von wachstumsfoerdernden Stoffen fuer therapeutische Zwecke | |
| Eriksen et al. | Fasciola hepatica: influence of extrahepatic adult flukes on infections and immunity in rats | |
| EP0445710A1 (de) | Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen | |
| DE1792256C3 (de) | Oral applizierbare, polyvalente Impfstoffe gegen lokale Darminfektionen | |
| DE1492243C3 (de) | Injizierbare Impfstoffe | |
| DE60213785T2 (de) | Saponin inaktivierte mykoplasma impfstoffe | |
| DE2611979A1 (de) | Mittel zur behandlung von blaehungen und durchfall bei tieren | |
| DE69420016T2 (de) | Verwendung eines TMA-Komplexes und/oder eines Fragmentes dieses TMA Komplexes für die Herstellung eines Arzneimittels für die Behandlung und/oder die Vorbeugung von Krebs | |
| DE2126957A1 (de) | Impfstoff gegen Gänsehepatitis | |
| DE3235913C2 (de) | Verfahren zur Gewinnung eines Krankheitskontrollprodukts | |
| Lämmler et al. | The efficacy of anthelmintics against third stage larvae of Ancylostoma caninum in Mastomys natalensis | |
| AT226368B (de) | Verfahren zur Herstellung einer Vaccine | |
| DE2015804A1 (de) | Verfahren zur Herstellung eines antigenen oder allergenen Extraktes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |